Overview
What it is.
Pentadeca Arginate is a modified peptide developed as a stability- and bioavailability-focused counterpart to BPC-157. Its research base is newer and smaller than BPC-157's, and it is studied largely alongside comparable tissue-repair-signaling questions.
Research Areas
- Studied for its potential role in tissue-repair-signaling research, building on BPC-157-adjacent research
- Studied for stability and bioavailability compared with related peptides
Batch & Testing
Proof, not promises.
COA ships with every order
Every batch we release is independently HPLC tested before it ever reaches a lab bench. Browse the full certificate library.
Research Deep-Dive
How it works.
Research Deep-Dive
How it works.
Pentadeca Arginate (PDA) is a peptide marketed as a next-generation alternative to BPC-157 — it uses the identical 15-amino-acid sequence as BPC-157, but paired with an arginine salt instead of the standard acetate salt. It emerged largely as a response to BPC-157's regulatory restrictions, positioned in marketing as a more stable, "legal" successor.
Because PDA shares BPC-157's exact amino acid sequence, any proposed mechanism — angiogenesis support, fibroblast activity, growth-factor interaction — is inherited from BPC-157 research rather than established independently. The arginine counterion is claimed to improve chemical stability, but that is a formulation change, not a different biological mechanism.
Use Cases Explored
- Marketed (not independently studied) as an alternative to BPC-157 for tissue-repair-adjacent research interest
- Discussed in stability/formulation contexts relative to BPC-157 acetate
The Evidence
No PDA-specific research exists
As of 2026, there are no peer-reviewed studies evaluating pentadeca arginate as its own molecule and no human clinical trials — a fact multiple independent reviews converge on. Everything claimed about PDA is extrapolated from BPC-157 studies, which were conducted on the acetate salt, not the arginate form.
Unverified stability claim
A widely repeated marketing claim that the arginate salt is dramatically more stable than BPC-157 acetate at stomach-acid pH has not been published in any peer-reviewed journal.
Inherited BPC-157 evidence limits
Even the BPC-157 evidence PDA borrows from is thin in humans — a 2025 systematic review found only one human study (an uncontrolled 12-patient case series) among 36 included papers. Regulatory analysis has also found PDA meets none of the standard criteria for legitimate 503A pharmacy compounding.
Specifications
The essentials.
Specifications
The essentials.
- Vial Capacity
- 3 ml glass vial
- Form
- Lyophilized powder
- Solubility
- Reconstitute with bacteriostatic water
- Storage
- Store in a cool, dry place. Refrigerate at 2–8°C after reconstitution
- Shelf Life
- 24 months lyophilized; 4–6 weeks refrigerated after reconstitution
Questions
Pentadeca Arginate FAQ
Questions
Pentadeca Arginate FAQ
How does Pentadeca Arginate's research base compare with BPC-157's?+
It's considerably smaller and newer — much of what's discussed about it draws on BPC-157-adjacent research rather than PDA-specific studies.
Tissue Repair
Pentadeca Arginate
PDA
A newer, arginine-modified peptide studied as a stability-focused counterpart to BPC-157.
Size
COA-backed guarantee — independently test any vial; if it's under 99% purity, full refund + testing costs covered.
All products sold by One Tap Peptides are intended for laboratory research use only. Not for human consumption. Not intended for animal use. Not intended for diagnostic or therapeutic purposes.
Related
